18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Assessment of Occult Primary Head and Neck Cancers — An Audit and Review of Published Studies-Reference-Cited by-同舟云学术

18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Assessment of Occult Primary Head and Neck Cancers — An Audit and Review of Published Studies

Published:2012-04 Issue:3 Volume:24 Page:190-195
ISSN:0936-6555
Container-title:Clinical Oncology
language:en
Short-container-title:Clinical Oncology

Author:

Wong W.L.,Sonoda L.I.,Gharpurhy A.,Gollub F.,Wellsted D.,Goodchild K.,Lemon C.,Farrell R.,Saunders M.

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology

Reference24 articles.

1. The impact of FDG PET on the management of occult primary head and neck tumours;Wong;Clin Oncol (R Coll Radiol),2003

2. Role of PET FDG in the management of head and neck squamous cell cancer;Wong;Clin Oncol (R Coll Radiol),1998

3. Implication of 18F-fluoro-2-deoxy-D-glucose positron emission tomography on management of carcinoma of unknown primary in the head and neck: a Danish cohort study;Johansen;Laryngoscope,2002

4. 2[F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation;Jungehülsing;Otolaryngol Head Neck Surg,2000

5. [Positron emission tomography for primary tumor detection in lymph node metastases with unknown primary tumor];Schipper;HNO,1996

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multifocal and Recurrent Tonsillar Squamous Cell Carcinoma;Cureus;2024-08-26

2. „Cancer of unknown primary origin“ – Stellenwert der Strahlentherapie in der multimodalen Behandlung;Die Onkologie;2024-02-01

3. Stellenwert der PET-Bildgebung bei Kopf-Hals-Tumoren;Die Radiologie;2023-11-08

4. Stellenwert der PET-Bildgebung bei Kopf-Hals-Tumoren;best practice onkologie;2023-11

5. Stellenwert der PET-Bildgebung bei Kopf-Hals-Tumoren;HNO;2023-09-13